Surface modification of silicone breast implants by binding the antifibrotic drug halofuginone reduces capsular fibrosis

TY - JOUR

T1 - Surface modification of silicone breast implants by binding the antifibrotic drug halofuginone reduces capsular fibrosis

AU - Zeplin, Philip H

AU - Larena-Avellaneda, Axel

AU - Schmidt, Karsten

PY - 2010/7

Y1 - 2010/7

N2 - BACKGROUND: Capsular fibrosis is one of the most severe complications that can occur in connection with silicone breast implants. Should this case arise, a periprosthetic deposition of fibroid tissue may evolve. Transforming growth factor (TGF)-beta is one of the most important mediators in relation to such processes.METHODS: The chinazolinone derivative halofuginone is a type I collagen synthesis inhibitor that interferes with the TGF-beta signaling pathway. The work at hand examines the local antifibrotic effectiveness of halofuginone lactate, which has been biotechnologically bound to the silicone implant's surface. The experiments in relation to this were conducted in vivo on two groups of seven Sprague-Dawley rats. Group I received untreated silicone implants, and group II received halofuginone-coated silicone implants.RESULTS: Submusculary embedded halofuginone-coated silicone implants have shown no systemic side effects. The histologic and immunohistologic examinations of the periprostatic capsules revealed a significant decrease of CD68 histiocytes, TGF-beta, fibroblasts, collagen type I and type III, and capsular thickness after a 3-month period.CONCLUSION: The results confirmed a decrease in foreign body responses to halofuginone surface-modified silicone implants and mark their potential for obtaining a lessened capsular fibrosis by way of a local antifibrotic effect.

AB - BACKGROUND: Capsular fibrosis is one of the most severe complications that can occur in connection with silicone breast implants. Should this case arise, a periprosthetic deposition of fibroid tissue may evolve. Transforming growth factor (TGF)-beta is one of the most important mediators in relation to such processes.METHODS: The chinazolinone derivative halofuginone is a type I collagen synthesis inhibitor that interferes with the TGF-beta signaling pathway. The work at hand examines the local antifibrotic effectiveness of halofuginone lactate, which has been biotechnologically bound to the silicone implant's surface. The experiments in relation to this were conducted in vivo on two groups of seven Sprague-Dawley rats. Group I received untreated silicone implants, and group II received halofuginone-coated silicone implants.RESULTS: Submusculary embedded halofuginone-coated silicone implants have shown no systemic side effects. The histologic and immunohistologic examinations of the periprostatic capsules revealed a significant decrease of CD68 histiocytes, TGF-beta, fibroblasts, collagen type I and type III, and capsular thickness after a 3-month period.CONCLUSION: The results confirmed a decrease in foreign body responses to halofuginone surface-modified silicone implants and mark their potential for obtaining a lessened capsular fibrosis by way of a local antifibrotic effect.

KW - Animals

KW - Breast Implants

KW - Coated Materials, Biocompatible

KW - Collagen Type I/antagonists & inhibitors

KW - Disease Models, Animal

KW - Female

KW - Fibrosis/pathology

KW - Foreign-Body Reaction/pathology

KW - Mammary Glands, Animal/metabolism

KW - Piperidines/administration & dosage

KW - Protein Synthesis Inhibitors/administration & dosage

KW - Quinazolinones/administration & dosage

KW - Rats

KW - Rats, Sprague-Dawley

KW - Silicon

KW - Treatment Outcome

U2 - 10.1097/PRS.0b013e3181dbc313

DO - 10.1097/PRS.0b013e3181dbc313

M3 - SCORING: Journal article

C2 - 20595874

VL - 126

SP - 266

EP - 274

JO - PLAST RECONSTR SURG

JF - PLAST RECONSTR SURG

SN - 0032-1052

IS - 1

ER -